Concepedia

Kapil Mayawala

KM

Statistics

Publications

17

Citations

1.1K

H-Index

15

Active since

2004

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Delaware

The University of Sydney

Cornell University

Universidad de Navarra

Kapil Mayawala is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cancer therapeutics, and oncology.

Top concepts

Publications per year

2004–2023

17

Publications

17

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson et al. · Clinical Cancer Research · 2018 · 205 citations

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016 · 158 citations · Full text

, , +6

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Mallika Lala, Tommy Li, Dinesh P. de Alwis et al. · European Journal of Cancer · 2020 · 154 citations

, , +6

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma

MS Chatterjee, Jeroen Elassaiss‐Schaap, Andreas Lindauer et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 79 citations · Full text

, , +18

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Ravit Geva, Mark Voskoboynik, Konstantin Dobrenkov et al. · Cancer · 2020 · 65 citations · Full text

1–5 of 17